期刊文献+

多囊卵巢综合征患者血清Ghrelin水平测定及其意义 被引量:1

Clinical meaning of detectting serum ghrelin levels in polycystic ovary syndrome
下载PDF
导出
摘要 目的探讨血清生长素(Ghrelin)与多囊卵巢综合征(PCOS)的关系。方法选择PCOS患者35例(P-COS组)及正常体检者33例(对照组),两组服75 g葡萄糖粉后,分别检测空腹与服糖1、2 h血脂,基础血激素(雌激素、孕激素、卵泡刺激素、黄体生成素、泌乳素、睾酮、雄烯二酮)及Ghrelin水平,计算BMI、腰臀比(WHR)、胰岛素抵抗指数及敏感指数。结果 PCOS组BMI、TG、HDL、胰岛素抵抗指数、空腹胰岛素、Ghrelin、睾酮及雄烯二酮在空腹与服糖1、2 h均低于对照组(P<0.05或<0.01)。相关分析显示,血清Ghrelin与BMI、WHR、雄激素、雄烯二酮、空腹血糖呈负相关(r分别为-0.504、-0.336、-0.440、-0.432、-0.414,P均<0.05),与HDL呈正相关(r=0.357,P<0.05)。结论血清Ghrelin可能在PCOS的病理生理过程中发挥作用。 Objectives To study the relationship between serum ghrelin and polycystic ovary syndrom(PCOS).Methods 35 patients diagnosed PCOS were recruited,33 women were voluntary selected as non-PCOS group at the same time.After oral glucose tolerance test(OGTT),insulin serum lipid,based serum hormones of patients were measured.The body mass index(BMI),waist-hip ratio(WHR),insulin resistance index(IR) and insulin sensitivity index(ISI) were caculated.Results The serum ghrelin levers,BMI,FINS,1 hour and 2 hours insulin results,testosterone and androstendione,triglyceride and high-density lipoprotein and insulin resistant index in PCOS group were significantly decreased,compaired with normal group(P<0.05 or <0.01).The serum ghrelin levers was negatively correlated with BMI,WHR,testosterone,androstendione and FPG(r=-0.504、-0.336、-0.440、-0.432、-0.414,all P<0.05),and positively correlated with HDL(r=0.357,P<0.05).Conclusions Ghrelin could play a role in pathophysiology of PCOS.
出处 《山东医药》 CAS 2012年第9期55-57,共3页 Shandong Medical Journal
基金 全军医学科学技术研究"十一五"计划课题项目(06G006)
关键词 多囊卵巢综合征 生长素 胰岛素释放试验 血脂 polycystic ovary syndrome ghrelin insulin release test blood lipids
  • 相关文献

参考文献14

  • 1Finer N. Present and future pharmacological approaches [J].Br Med Bull, 1997, 53(2): 409-432.
  • 2Clapham J C, Arch J R, Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities[J]. Pharmacol Therapeut, 2001, 89(1): 81-121.
  • 3Hauner H. Current pharmacological approaches to the treatment of obesity [J]. Int J Obes Relat Metab Disord, 2001, 25(Suppl 1): S102-S106.
  • 4Wieland H A, Hamilton B S. Weighing the options in the pharmacotherapy of obesity [J]. Int J Clin Pharmacol Therapeut, 2001, 39(9): 406-414.
  • 5Zhang C B, Deng H K, Ding M X. The screening of components with anti-obesity and anti-hyperlipidemia activities from Chinese herbs [P]. CN: 1363686A, 2002-08-14.
  • 6Zhang C B, Deng H K, Ding M X. The components with anti-obesity and anti-hyperlipidemia activities in some Chinese herbs and the consequence drugs [P]. CN: 1363367A, 2002-08-14.
  • 7Zhang C B, Teng L, Shi Y, et al. Effect of emodin on proliferation and differentiation of 3T3-L1 preadipocyte and FAS activity [J]. Chin Med J, 2002, 115(7):1035-1038.
  • 8Poykko SM,Kellokoski E,Horkko S,et al.Low plasma ghrelin isassociated with isulin resistance,hypertension,and the prevalenceof type 2diabetes[J].Diabetes,2003,52(10):2546-2553.
  • 9Marzullo P,Verti B,Savia GS,et al.The relationship between ac-tive ghrelin levels and human obesity involves alterations in restingenergy expenditure[J].J Clin Endocrinol Metab,2004,89(2):936-939.
  • 10Takao T, Kohei H. Long-chain acyl-CoA synthetase from rat liver [J]. Method Enzymol, 1981, 71: 334-341.

共引文献1

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部